Cargando…
MON-LB025 An Artificially Low HbA1c as a Result of Dapsone Therapy
Since the 1970s, hemoglobin A1c (HbA1c) has been incorporated in clinical practice to monitor glycemic control. Furthermore, in 2010, the American Diabetes Association included HbA1c as a diagnostic criterion for diabetes. According to Zion Market Research, the global HbA1c market is expected to rea...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Endocrine Society
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550919/ http://dx.doi.org/10.1210/js.2019-MON-LB025 |